LT3074033T - Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai - Google Patents

Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai

Info

Publication number
LT3074033T
LT3074033T LTEP14816018.7T LT14816018T LT3074033T LT 3074033 T LT3074033 T LT 3074033T LT 14816018 T LT14816018 T LT 14816018T LT 3074033 T LT3074033 T LT 3074033T
Authority
LT
Lithuania
Prior art keywords
obesity
compounds
treatment
methods
Prior art date
Application number
LTEP14816018.7T
Other languages
English (en)
Lithuanian (lt)
Inventor
Umut Ozcan
Original Assignee
The Children`S Medical Center Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Children`S Medical Center Corporation filed Critical The Children`S Medical Center Corporation
Publication of LT3074033T publication Critical patent/LT3074033T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP14816018.7T 2013-11-26 2014-11-25 Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai LT3074033T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361908998P 2013-11-26 2013-11-26
PCT/US2014/067393 WO2015081093A1 (en) 2013-11-26 2014-11-25 Compounds for the treatment of obesity and methods of use thereof

Publications (1)

Publication Number Publication Date
LT3074033T true LT3074033T (lt) 2019-02-25

Family

ID=52134396

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14816018.7T LT3074033T (lt) 2013-11-26 2014-11-25 Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai

Country Status (18)

Country Link
US (1) US20160375039A1 (enExample)
EP (1) EP3074033B1 (enExample)
JP (2) JP6672157B2 (enExample)
AU (2) AU2014354831B2 (enExample)
CA (1) CA2931826C (enExample)
CY (1) CY1122551T1 (enExample)
DK (1) DK3074033T3 (enExample)
ES (1) ES2709976T3 (enExample)
HR (1) HRP20190219T1 (enExample)
HU (1) HUE042196T2 (enExample)
LT (1) LT3074033T (enExample)
PL (1) PL3074033T3 (enExample)
PT (1) PT3074033T (enExample)
RS (1) RS58422B1 (enExample)
SI (1) SI3074033T1 (enExample)
SM (1) SMT201900064T1 (enExample)
TR (1) TR201901299T4 (enExample)
WO (1) WO2015081093A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153933A1 (en) * 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN106008657B (zh) * 2016-05-20 2017-11-21 天津中医药大学 苦蘵苦素i及提取方法及用途
IT201800005336A1 (it) * 2018-05-14 2019-11-14 Composizioni per uso nel trattamento dell’obesità
US20210106525A1 (en) * 2019-10-11 2021-04-15 Massachusetts Institute Of Technology Formulations for gastrointestinal delivery of oligonucleotides
CN113599502A (zh) * 2021-07-22 2021-11-05 廖儒佳 一种醉茄素a和瘦素的组合物及其在制备预防和或治疗出血性脑卒中药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
AU6028396A (en) 1995-06-07 1996-12-30 Amgen, Inc. Ob protein compositions and method
WO1997002004A2 (en) 1995-06-30 1997-01-23 Eli Lilly And Company Methods for treating diabetes
AU6688896A (en) 1995-08-17 1997-03-12 Amgen, Inc. Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
DK0866720T3 (da) 1995-11-22 2004-06-14 Amgen Inc OB-protein til forögelse af mager kropsmasse
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
WO1997038014A1 (en) 1996-04-04 1997-10-16 Amgen Inc. Fibulin pharmaceutical compositions and related methods
WO1997048419A1 (en) * 1996-06-20 1997-12-24 Merck & Co., Inc. Gene therapy for obesity
CA2263826A1 (en) 1996-08-30 1998-03-05 Amgen Inc. Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor
RU2201249C2 (ru) 1996-09-20 2003-03-27 Хехст Акциенгезелльшафт Применение антагонистов лептина для лечения резистентности к инсулину при диабете ii типа
DE69730093T2 (de) 1996-10-31 2006-07-20 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter Freisetzung
CN1195858C (zh) 1996-12-20 2005-04-06 安姆根有限公司 Ob融合蛋白组合物及方法
CA2286098C (en) 1997-04-17 2009-07-07 Amgen Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
WO1998055139A1 (en) 1997-06-06 1998-12-10 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
WO2000009165A1 (en) 1998-08-10 2000-02-24 Amgen Inc. Dextran-leptin conjugates, pharmaceutical compositions and related methods
JP2002526780A (ja) 1998-10-02 2002-08-20 アムジエン・インコーポレーテツド レプチン処置に対する素因の決定方法
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
DE60027409T2 (de) 1999-02-12 2007-04-12 Amgen Inc., Thousand Oaks Glykosylierte leptinzusammensetzungen und zugehörige verfahren
AU2002359288B2 (en) 2001-10-22 2008-07-31 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
WO2004039832A2 (en) 2002-10-31 2004-05-13 Albany Medical College Leptin-related peptides
JP4585186B2 (ja) * 2003-07-31 2010-11-24 杏林製薬株式会社 肥満、糖尿病及び脂質代謝異常の新規な予防又は治療剤
ES2366958T3 (es) * 2006-06-23 2011-10-27 Laboratorios Del Dr. Esteve, S.A. Combinación de un inhibidor de la colinesterasa y un compuesto con afinidad por el receptor 5-ht6.
US20110230551A1 (en) * 2008-09-15 2011-09-22 Leslie Gunatilaka Withaferin a analogs and uses thereof
WO2010053655A2 (en) * 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
US8598339B2 (en) * 2011-02-01 2013-12-03 University Of Kansas Withanolide isolated from Physalis longifolia and analogs and methods of use thereof

Also Published As

Publication number Publication date
SI3074033T1 (sl) 2019-03-29
AU2018200517B2 (en) 2019-12-19
EP3074033A1 (en) 2016-10-05
US20160375039A1 (en) 2016-12-29
ES2709976T3 (es) 2019-04-22
HUE042196T2 (hu) 2019-06-28
PT3074033T (pt) 2019-02-08
AU2014354831B2 (en) 2017-10-26
CA2931826A1 (en) 2015-06-04
TR201901299T4 (tr) 2019-02-21
JP6672157B2 (ja) 2020-03-25
RS58422B1 (sr) 2019-04-30
CY1122551T1 (el) 2021-01-27
SMT201900064T1 (it) 2019-02-28
CA2931826C (en) 2021-11-16
EP3074033B1 (en) 2018-11-07
JP2016537431A (ja) 2016-12-01
AU2018200517A1 (en) 2018-02-15
JP2020059744A (ja) 2020-04-16
HRP20190219T1 (hr) 2019-03-22
WO2015081093A1 (en) 2015-06-04
AU2014354831A1 (en) 2016-06-09
PL3074033T3 (pl) 2019-08-30
DK3074033T3 (en) 2019-02-11

Similar Documents

Publication Publication Date Title
IL273090B (en) Methods and preparations for the treatment of cancer
IL243976B (en) kdm1a inhibitors for disease treatment
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
GB201320729D0 (en) Therapeutic compounds and their use
IL244014A0 (en) Combined therapy for the treatment of glioblastoma
GB201320723D0 (en) Composition and methods of treatment
PL3021838T3 (pl) Leczenie otyłości
SG11201509782TA (en) Compositions and methods for the treatment of diabetes and pre-diabetes
PT2900230T (pt) Compostos para o tratamento de obesidade e métodos de utilização dos mesmos
GB201311361D0 (en) Compounds and their therapeutic use
IL247325A0 (en) Therapeutic methods using noribogaine and related compounds
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
LT3074033T (lt) Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
GB201309375D0 (en) Medical methods and compounds for medical use
GB201308736D0 (en) Compounds and their therapeutic use
GB201309376D0 (en) Medical methods and compounds for medical use
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
GB201308665D0 (en) Device for the treatment of bone conditions
AU2013900139A0 (en) Device for the treatment of snoring
GB201309379D0 (en) Medical methods and compounds for medical use
GB201317804D0 (en) Therapeutic compounds and their use
GB201316173D0 (en) Compounds and their therapeutic use
GB201307677D0 (en) Compounds and their therapeutic use